Drug discovery

#Drug development #Drug discovery #Immunobiology #Research

Stem cells use same method as plants and insects to protect against viruses

Researchers at the Francis Crick Institute have found a vital mechanism, previously thought to have disappeared as mammals evolved, that helps protect mammalian stem cells from RNA viruses such as SARS-CoV-2 and Zika virus. The scientists suggest this could one day be exploited in the development of new antiviral treatments. Read More

#News

#Biomarkers #Drug development #Drug discovery #Neuroscience #Novel therapeutics #Therapeutics

Biomarker company raises £2.6 million for neuroscience drugs

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Biomarkers #Drug delivery #Drug discovery #Drug screening #High throughput screening #Webinar

Webinar: Enabling biomarker discovery and screening

Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More

#News

#Biologics / Biotechnology #Bioscience #Biotechnology #Drug delivery #Drug development #Drug discovery

Switzerland: punching above its weight as global biotech hub

Listen to this article on the DDW Podcast:   To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman spoke to Michael Altorfer (CEO of the Swiss Biotech Association), Jan Lucht (Head of Biotechnology, scienceindustries), Claude Joris (Secretary General, BioAlps), and Carole Delauney (Business Development… Read More

#Editor's Choice #Exclusive Content #Market Reports #News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Drug screening #High throughput screening

What will this NIGMS grant mean for combatting rare diseases?

Sinopia Biosciences has been awarded a grant from the National Institute of General Medical Sciences (NIGMS), as part of the National Institutes of Health, to further develop and validate their proprietary metabolomics-based high-throughput screening (HTS) platform with an initial focus on rare diseases. To date, Sinopia has received nearly $8… Read More

#News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News

#Clinical trials #Drug development #Drug discovery #Research #Sclerosis

Gesynta Pharma announces significant progress across new drug candidate

Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More

#News

#Covid-19 #Drug development #Drug discovery #Drug targets

Targeted treatments for respiratory infections

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON… Read More

#News

#Drug discovery #Genetics / genomics #Genomics

Reproducibility in single cell genomic analysis

Listen to this article on the DDW Podcast: By Andrew Gane, Diagnostics Strategy & Technology Manager, Cytiva A cell is a base unit in biology where the genome is transcribed and translated into function. Our traditional understanding of cells rests heavily on studying cells in tissues as an identical… Read More

#Exclusive Content #News

#Covid-19 #Drug development #Drug discovery #mRNA

Can antiviral oligonucleotides better prepare us for the next pandemic?

Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More

#Exclusive Content #News

#CAR-T #Drug discovery #Immuno-oncology #Immunotherapy #Institute of Cancer Research

Immune checkpoint inhibitors: What are the risks?

Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More

#Cancer Research #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery

163% growth in recruiting clinical trial sites in China

Virtual clinical development specialist Phesi has released its analysis of the growth in recruiting clinical trial sites in China since the beginning of 2018. The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021. While… Read More

#News

#Biotherapeutics #Clinical trials #Drug discovery #Life sciences

Awakn Life Sciences: new CRO and patent application

Awakn Life Sciences has appointed neuroscientist and addiction researcher, Professor David Nutt as Chief Research Officer as well as announcing the filing of patent applications in the US for two next-generation novel MDMA-derived new chemical entities. This executive appointment is driven by the expansion of Awakn’s psychedelic drug and therapy… Read More

#News

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News